Jonathan A. Bernstein
Experienced in Genital Dwarfism

Dr. Jonathan A. Bernstein

Medical Genetics | Pediatrics
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 
Experienced in Genital Dwarfism
Lpch Medical Group Div Of Lucile
725 Welch Rd, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Bernstein is a Medical Genetics specialist and a Pediatrics provider in Palo Alto, California. Dr. Bernstein and is rated as an Experienced provider by MediFind in the treatment of Genital Dwarfism. His top areas of expertise are Hereditary Angioedema, Chronic Spontaneous Urticaria (CSU), Polysyndactyly Cardiac Malformation, and Chronic Cough.

His clinical research consists of co-authoring 613 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Genital Dwarfism.

Specialties
Medical Genetics
Pediatrics
Licenses
Medical Biochemical Genetics in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

LPCH MEDICAL GROUP DIV OF LUCILE
725 Welch Rd, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2024
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
Enrollment Status: Completed
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: Dupilumab
Study Phase: Phase 4
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
Enrollment Status: Completed
Publish Date: February 01, 2023
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Biological
Study Phase: Phase 4
View 11 Less Clinical Trials

603 Total Publications

De novo variants in KDM2A cause a syndromic neurodevelopmental disorder.
De novo variants in KDM2A cause a syndromic neurodevelopmental disorder.
Journal: medRxiv : the preprint server for health sciences
Published: April 16, 2025
Similar Doctors
Experienced in Genital Dwarfism
Dr. Natalia Gomez-Ospina
Medical Genetics | Pediatrics
Experienced in Genital Dwarfism
Dr. Natalia Gomez-Ospina
Medical Genetics | Pediatrics
1804 Embarcadero Rd, Ste 100, 
Palo Alto, CA 
 (3.4 mi)
650-497-8000
Experience:
14+ years
Languages Spoken:
English

Natalia Gomez-Ospina is a Medical Genetics specialist and a Pediatrics provider in Palo Alto, California. Dr. Gomez-Ospina has been practicing medicine for over 14 years and is rated as an Advanced provider by MediFind in the treatment of Genital Dwarfism. Her top areas of expertise are Ohdo Syndrome, Say-Barber-Biesecker-Young-Simpson Variant, Myhre Syndrome, Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Micrognathia.

Experienced in Genital Dwarfism
Dr. Christina G. Tise
Medical Genetics
Experienced in Genital Dwarfism
Dr. Christina G. Tise
Medical Genetics

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 mi)
650-498-7200
Languages Spoken:
English

Christina Tise is a Medical Genetics provider in Palo Alto, California. Dr. Tise and is rated as an Advanced provider by MediFind in the treatment of Genital Dwarfism. Her top areas of expertise are Zellweger Syndrome, Coffin-Lowry Syndrome, Adrenoleukodystrophy (ALD), and 2q37 Deletion Syndrome.

Experienced in Genital Dwarfism
Dr. Suha Bachir
Medical Genetics
Experienced in Genital Dwarfism
Dr. Suha Bachir
Medical Genetics

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 mi)
650-498-7200
Experience:
14+ years
Languages Spoken:
English

Suha Bachir is a Medical Genetics provider in Palo Alto, California. Dr. Bachir has been practicing medicine for over 14 years and is rated as an Experienced provider by MediFind in the treatment of Genital Dwarfism. Her top areas of expertise are 2q37 Deletion Syndrome, Genital Dwarfism, Robinow Syndrome, and Neurofibromatosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernstein's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile